ESR1 and COVID-19: Compared with patients without myocardial injury, patients with myocardial injury presented with more severe NCP type (72.2% vs. 31%), more cardiovascular disease (CVD, 33.3% vs. 13.8%), and higher mortality rate (61.1% vs. 6.9%), manifested by abnormal laboratory findings, such as older age, higher levels of CRP, ESR, SAA, IL-6, TNI, AST, ALP, and urea nitrogen, demonstrating that cardiac injury in COVID-19 patients was associated with major adverse clinical outcomes.